Exxaro Tiles manufactures and sells vitrified floor and wall tiles, specializing in double-charge and glazed finishes for residential and commercial construction markets.
The company operates in a highly commoditized and fragmented industry where low ROCE (6.9%) and razor-thin net margins (2.6%) contradict any claims of a brand or cost moat. Despite high capacity utilization of 80%, the company lacks pricing power, as evidenced by declining revenues and profits during periods of input cost volatility.
Capital has been deployed into capacity upgrades and solar projects, yet these investments have failed to generate meaningful incremental returns, with EPS declining at a 37.7% CAGR. The company has suspended dividends to conserve liquidity, reflecting tight cash flow despite a reasonable debt-to-equity ratio.
The company's collapse was driven by a lethal combination of stagnant growth and eroding margins in a commoditized market. Management's capital allocation into capacity upgrades failed to yield incremental returns, while interest coverage ratios tightened to the point of insolvency during a cyclical downturn. The lack of pricing power meant input cost spikes could not be passed on, and the persistent discrepancies in inventory valuation eventually culminated in a massive write-down that wiped out shareholder equity.
RichFakir rates Exxaro Tiles Ltd's business quality as poor — 23/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Exxaro Tiles Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Exxaro Tiles Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Exxaro Tiles Ltd's fair value is about ₹2 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →